Advertisement
|
|
news roundup
This month's moves and news includes updates from PHASTAR, Signant Health, Clinithink, CROMSOURCE and ERT.
| advertisement
Launching Medical Devices in the Japanese Market
- How to navigate regulatory and reimbursement approval
Thursday, October 31, 2019 at 11am EDT
 Register Now
|
Signant Health's TrialConsent solution has been selected to provide electronic informed consent for an investigator-led schizophrenia trial at the Shanghai Mental Health Center in China.
|
|
|
Subscribe
 |
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers » |
|
|
|
Advertisement
|
|
| advertisement
GrantPlan: Create Grant Budgets with Confidence and Accuracy
Thursday, October 10, 2019 at 11am EDT
 Register Now |
Elligo Health Research's clinical research services are being employed by Jack Nathan Health to help patients gain access to clinical research as a care option at its Canadian Walmart clinics.
| advertisement
Begin with the End in Mind: The Strategic Benefit of Coordinating Site Budgeting, Contracting, & Payments
Wednesday, October 2, 2019 at 11am EDT
 Register Now |
PPD is expanding its bioanalytical laboratory in Richmond, VA. The expansion adds enhancements to its vaccine sciences, biomarker, genomics and automation services, as well 200 new positions.
| advertisement
How AI/ML and advanced techniques are enhancing clinical development
Lessons learned from use in study design, patient and site ID, safety, and risk-based monitoring
Tuesday, October 1, 2019 at 11am EDT
 Register Now |
Articles
Joel B. Selzer, co-founder and CEO, ArcheMedX, discusses the impact that healthcare technology has on clinical trials, focusing on the development of the company's workforce readiness platform.
|
|
|
| advertisement
Successful Early Phase Drug Development of mAb Drugs
Europe: Thursday, September 26, 2019 at 3pm BST | 4pm CEST
North America: Thursday, October 3, 2019 at 11am EDT | 10am CDT | 8am PDT
 Register Now |
|
A recent industry panel finds that two years after ICH E6 (R2)'s ratification, an industry-wide shift towards Risk-Based Study Execution (RBx) is reducing risk, improving oversight and boosting proactive, predictive decision making.
Blog Posts
In this opinion, the author describes the many steps organizations can take to implement a site-first approach that ensures their technology tools aren't missing the mark.
Editor Lisa Henderson highlights the September issue on the Changing Site Landscape, as well as opinions around the industry on specific site issues.
|
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription |
|
|
|
|
|
